Andere talen Acura Pharmaceuticals, Inc.

Aandelen

ACUR

US00509L8028

Beurs gesloten - OTC Markets Andere beurzen 21:39:25 03-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,0041 ^USD	+36,67%		-59,00%	+4.000,00%

26/03	Acura Pharmaceuticals, Inc. kondigt wijziging aan van de overeenkomst met Abuse Deterrent Pharma, LLC	CI
2023	Acura Pharmaceuticals, Inc. kondigt pensionering en ontslag aan van de heer Bruce F. (Toby) Wesson als lid van de Raad van Bestuur	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Acura Pharmaceuticals : TO LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT - Form 8-K	26/03
Acura Pharmaceuticals, Inc. Announces Amendment to the Agreement with Abuse Deterrent Pharma, LLC	26/03
Acura Pharmaceuticals, Inc. announced that it has received $0.25 million in funding from Abuse Deterrent Pharma, LLC	14/03
Acura Pharmaceuticals, Inc. Receives $250,000 Loan from Abuse Deterrent Pharma, LLC	14/02
Acura Pharmaceuticals, Inc. announced that it has received $0.25 million in funding	14/02
Acura Pharmaceuticals : AMENDED, CONSOLIDATED AND RESTATED SECURED PROMISSORY NOTE - Form 8-K	21/12
Acura Pharmaceuticals, Inc. and Abuse Deterrent Pharmaceuticals, LLC Enter into Amendment #1 to the November 10, 2022 Amended, Consolidated and Restated Secured Promissory Note	21/12
Acura Pharmaceuticals : New Financial Obligation - Form 8-K	06/12
Acura Pharmaceuticals, Inc. Announces Retirement and Resignation of Mr. Bruce F. Wesson as Member of Board of Directors	25-09-23
Acura Pharmaceuticals, Inc. Provides Update Related to LTX-03 (Hydrocodone Bitartrate and Acetaminophen) Tablets	31-08-23
Acura Pharmaceuticals, Inc. Announces Preliminary Topline Results from Study AP-LTX-311 Successfully Demonstrated That A Nine-Tablet Dose of Ltx-03	30-08-23
Acura Pharmaceuticals : Termination of Material Agreement - Form 8-K	16-08-23
Acura Pharmaceuticals, Inc. and Zyla Life Sciences, LLC Agree to Terms for the Termination of the Collaboration and License Agreement	16-08-23
Acura Pharmaceuticals, Inc. Receives $250,000 Loan from Abuse Deterrent Pharma, LLC	28-07-23
Acura Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	30-06-23
Acura Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2021	30-06-23
Acura Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	30-06-23
Acura Pharmaceuticals : TO LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT - Form 8-K	28-06-23
Acura Pharmaceuticals, Inc. Enters into an Agreement to Further Amend the June 28, 2019 License, Development and Commercialization Agreement with Abuse Deterrent Pharma, LLC	28-06-23
Acura Pharmaceuticals, Inc. Receives $150,000 Loan from Abuse Deterrent Pharma, LLC	26-05-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Acura Pharmaceuticals, Inc.

Aandelen

ACUR

US00509L8028

Andere talen

Filters